[{"orgOrder":0,"company":"Drugs for Neglected Diseases","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Drugs for Neglected Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Drugs for Neglected Diseases \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Drugs for Neglected Diseases \/ Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Swiss TPH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bayer AG \/ Swiss TPH","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Swiss TPH"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Bayer AG | Silicon Valley Community Foundation | University of the Philippines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines"}]

Find Clinical Drug Pipeline Developments & Deals for Emodepside

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Swiss Tropical and Public Health Institute

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Swiss Tropical and Public Health Institute

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 29, 2025

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Bayer AG | Silicon Valley Community Foundation | University of the Philippines

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Swiss Tropical and Public Health Institute

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Swiss Tropical and Public Health Institute

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 14, 2024

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          July 20, 2023

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Swiss TPH

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 06, 2022

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Bayer AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 26, 2017

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 26, 2017

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Drugs for Neglected Diseases

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 22, 2016

                          Lead Product(s) : Emodepside

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank